Download PDF
PiD - Psychotherapie im Dialog 2022; 23(01): 17-22
DOI: 10.1055/a-1477-1044
Standpunkte

Essstörungen – State of the Art und neuere Entwicklungen

Tabea Bauman
,
Ulrich Voderholzer
› Further Information
Also available at
    Permissions and Reprints

Einer leitliniengerechten Versorgung der Essstörungen kommt aufgrund der potenziell schwerwiegenden körperlichen und psychosozialen Beeinträchtigungen eine hohe Bedeutung zu. Der Beitrag zeigt die Empfehlungen der S3-Leitlinie zur psychotherapeutischen und psychopharmakologischen Behandlung der Anorexia nervosa, Bulimia nervosa und Binge-Eating-Störung und berichtet über neuere Entwicklungen in der Behandlung der Essstörungen.



Publication History

Article published online:
18 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Garber AK, Cheng J, Accurso EC. et al. Short-term outcomes of the study of refeeding to optimize inpatient gains for patients with anorexia nervosa: A multicenter randomized clinical trial. JAMA Pediatr 2021; 175: 19-27
    CrossrefPubMedSearch in Google Scholar
  • 2 Haas V, Kohn M, Körner T. et al. Practice-based evidence and clinical guidance to support accelerated re-nutrition of patients with anorexia nervosa. J Am Acad Child Adolesc Psy 2021; 60: 555-561
    CrossrefPubMedSearch in Google Scholar
  • 3 Voderholzer U, Haas V, Correll CU. et al. Medical management of eating disorders: an update. Curr Opin Psy 2020; 33: 542-553
    CrossrefPubMedSearch in Google Scholar
  • 4 Zipfel S, Wild B, Groß G. et al. ANTOP study group. Focal psychodynamic therapy, cognitive behaviour therapy, and optimised treatment as usual in outpatients with anorexia nervosa (ANTOP study): randomised controlled trial. Lancet 2014; 383: 127-137
    CrossrefPubMedSearch in Google Scholar
  • 5 Lock J. Family therapy for eating disorders in youth: current confusions, advances, and new directions. Curr Opin Psy 2018; 31: 431-435
    CrossrefPubMedSearch in Google Scholar
  • 6 Linardon J, Fairburn CG, Fitzsimmons-Craft EE. et al. The empirical status of the third-wave behaviour therapies for the treatment of eating disorders: A systematic review. Clin Psychol Rev 2017; 58: 125-140
    CrossrefPubMedSearch in Google Scholar
  • 7 Koskina A, Campbell IC, Schmidt U. Exposure therapy in eating disorders revisited. Neurosci Biobeh Rev 2013; 37: 193-208
    CrossrefPubMedSearch in Google Scholar
  • 8 Dittmer N, Voderholzer U, Mönch C. et al. Efficacy of a specialized group intervention for compulsive exercise in inpatients with anorexia nervosa: A randomized controlled trial. Psychother Psychosom 2020; 89: 161-173
    CrossrefPubMedSearch in Google Scholar
  • 9 Lonergan AR, Bussey K, Fardouly J. et al. Protect me from my selfie: Examining the association between photo-based social media behaviors and self-reported eating disorders in adolescence. Int J Eat Disord 2020; 53: 485-496
    CrossrefPubMedSearch in Google Scholar
  • 10 Neumayr C, Voderholzer U, Tregarthen J. et al. Improving aftercare with technology for anorexia nervosa after intensive inpatient treatment: A pilot randomized controlled trial with a therapist-guided smartphone app. Int J Eat Disord 2019; 52: 1191-1201
    CrossrefPubMedSearch in Google Scholar
  • 11 Attia E, Steinglass JE, Walsh BT. et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: A randomized clinical trial. Am J Psy 2019; 176: 449-456
    CrossrefPubMedSearch in Google Scholar
  • 12 Milos G, Antel J, Kaufmann LK. et al. Short-term metreleptin treatment of patients with anorexia nervosa: Rapid on-set of beneficial cognitive, emotional, and behavioral effects. Transl Psych 2020; 10: 303
    CrossrefPubMedSearch in Google Scholar
  • 13 Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psy 1992; 49: 139-147
    CrossrefPubMedSearch in Google Scholar
  • 14 Goldstein DJ, Wilson MG, Ascroft RC. et al. Effectiveness of Fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord 1999; 25: 19-27
    CrossrefPubMedSearch in Google Scholar
  • 15 Hilbert A, Petroff D, Herpertz S. et al. Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. J Consult Clin Psychol 2019; 87: 91-105
    CrossrefPubMedSearch in Google Scholar
  • 16 Hudson JI, McElroy SL, Ferreira-Cornwell MC. et al. Efficacy of Lisdexamfetamine in adults with moderate to severe binge-eating disorder: A randomized clinical trial. JAMA Psy 2017; 74: 903-910
    PubMedSearch in Google Scholar
  • 17 Austin A, Flynn M, Richards K. et al. Duration of untreated eating disorder and relationship to outcomes: A systematic review of the literature. Eur Eat Disord Rev 2021; 29: 329-345
    CrossrefPubMedSearch in Google Scholar
  • 18 Flynn M, Austin A, Lang K. et al. Assessing the impact of first episode rapid early intervention for eating disorders on duration of untreated eating disorder: A multi-centre quasi-experimental study. Eur Eat Disord Rev 2021; 29: 458-471
    CrossrefPubMedSearch in Google Scholar